Ask
Search
My library
ORKG

ORKG Ask

Our mission is to organize scholarly knowledge and make it accessible to humans and machines.

About

About ORKG Ask
Report issue
Statistics
Contact

Legal

Terms of use
Data protection (sheet)
Imprint
Accessibility
License

Technical

We
open source
System status
Changelog
Frontend: v1.41.0
Backend: v1.13.4

We use cookies to provide a better user experience.

Data Protection

Intervention dose prescribed and adherence over the 12 month study period.

Catherine Sherrington (624773)
Stephen R. Lord (385500)
Constance M. Vogler (624774)
Jacqueline C. T. Close (624775)
Kirsten Howard (137555)
Catherine M. Dean (624776)
Gillian Z. Heller (624777)
Lindy Clemson (624778)
Sandra D. O'Rourke (624779)
Elisabeth Ramsay (624780)
Elizabeth Barraclough (624781)
Robert D. Herbert (624782)
Robert G. Cumming (341277)

Publication date

September 2014

DOI

10.1371/journal.pone.0104412.t003

Abstract

<p>Intervention dose prescribed and adherence over the 12 month study period.</p

Extracted data

Related items

Observed average monthly HTS and VMMC rates by study condition, over entire study period and within the first six months of intervention implementation.

Stephen M. Weiss (6804122)
Kasonde Bowa (2813896)
Robert Zulu (16813963)
Violeta J. Rodriguez (3174705)
Ryan R. Cook (8812859)
Deborah L. Jones (3174693)

January 2024

Observed average monthly HTS and VMMC rates by study condition, over entire study period and within ...

Drug resistance and treatment efficacy in the group infected with subtype D.

Miłosz Parczewski (332730)
Magdalena Leszczyszyn-Pynka (332731)
Dorota Bander (332732)
Anna Urbanska (332734)
Anna Boroń-Kaczmarska (332736)

February 2013

<p>*Percentage expressed adherence based on the number of months of medications dispensed by the num...

For all study patients, patient median Hb, median TSAT, mean IV iron and mean EPO administered in the protocol period 12 months before study start and the 18-month CQI period.

Jonathan A. Lorch (566667)
Victor E. Pollak (566668)

May 2014

<p>For all study patients, patient median Hb, median TSAT, mean IV iron and mean EPO administered in...

Outcomes at 12 months follow-up compared between the intervention and the control groups.

Anna Barker (3448526)
Peter Cameron (848182)
Leon Flicker (95283)
Glenn Arendts (84730)
Caroline Brand (3448523)
Christopher Etherton-Beer (398694)
Andrew Forbes (454446)
Terry Haines (3631453)
Anne-Marie Hill (415096)
Peter Hunter (222839)
Judy Lowthian (3566432)
Samuel R. Nyman (6733592)
Julie Redfern (3221304)
De Villiers Smit (6733595)
Nicholas Waldron (3500894)
Eileen Boyle (6733598)
Ellen MacDonald (6733601)
Darshini Ayton (4065070)
Renata Morello (3448529)
Keith Hill (4065067)

May 2019

Outcomes at 12 months follow-up compared between the intervention and the control groups.</p

Treatment parameters of the two study groups at the baseline and during follow-up period.

Luciano A. Pedrini (6392159)
Adam M. Zawada (847589)
Anke C. Winter (6392162)
Jenny Pham (6392165)
Gudrun Klein (6392168)
Melanie Wolf (3103785)
Astrid Feuersenger (6392171)
Pio Ruggiero (6392174)
Annalisa Feliciani (6392177)
Carlo Barbieri (848258)
Adelheid Gauly (355519)
Bernard Canaud (177330)
Stefano Stuard (2552848)

February 2019

Treatment parameters of the two study groups at the baseline and during follow-up period.</p

Adherence to clinical preventive recommendations among diabetes patients according to study variables.

Isabel Jimenez-Trujillo (509331)
Rodrigo Jiménez-García (320379)
Jesus Esteban-Hernández (2209084)
Valentin Hernández-Barrera (2209078)
Pilar Carrasco Garrido (2209075)
Miguel A. Salinero-Fort (310193)
Juan Cardenas-Valladolid (2209081)
Ana López-de-Andrés (2190292)

June 2015

<p>Adherence to clinical preventive recommendations among diabetes patients according to study varia...

Cost-effectiveness acceptability curve: proportion adherent over the intervention period.

Catherine Henderson (811342)
Martin Knapp (146158)
Ksenija Yeeles (342120)
Stephen Bremner (119242)
Sandra Eldridge (80747)
Anthony S. David (720515)
Nicola O’Connell (645718)
Tom Burns (811343)
Stefan Priebe (117382)

October 2015

<p>Cost-effectiveness acceptability curve: proportion adherent over the intervention period.</p

Treatment efficacy during the 12-week observation period: Control vs. FMT groups (intention-to-treat [ITT] and per-protocol [PP] analysis).

Hongliang Tian (529301)
Xiaolong Ge (1758829)
Yongzhan Nie (124038)
Linfeng Yang (516708)
Chao Ding (1402099)
Lynne V. McFarland (3716476)
Xueying Zhang (460267)
Qiyi Chen (1663033)
Jianfeng Gong (177593)
Ning Li (45258)

February 2017

<p>Treatment efficacy during the 12-week observation period: Control vs. FMT groups (intention-to-tr...

Change in steps/day between baseline and 12-month follow-up after a behavioral physical activity intervention.

Maria Koreny (54716)
Heleen Demeyer (500670)
Ane Arbillaga-Etxarri (845881)
Elena Gimeno-Santos (845883)
Anael Barberan-Garcia (845884)
Marta Benet (188966)
Eva Balcells (582606)
Eulàlia Borrell (6714437)
Alicia Marin (1653766)
Diego A. Rodríguez Chiaradía (6714440)
Pere Vall-Casas (845887)
Jordi Vilaró (845886)
Robert Rodríguez-Roisin (6714443)
Judith Garcia-Aymerich (582609)

May 2019

Change in steps/day between baseline and 12-month follow-up after a behavioral physical activity int...

Outcome measure summary statistics and intervention effects at 3, 6, and 12 months.

Karina Lovell (52502)
Peter Bower (52501)
Judith Gellatly (4175419)
Sarah Byford (405086)
Penny Bee (456567)
Dean McMillan (628092)
Catherine Arundel (3558773)
Simon Gilbody (52503)
Lina Gega (4175413)
Gillian Hardy (3807229)
Shirley Reynolds (4175416)
Michael Barkham (615633)
Patricia Mottram (4175431)
Nicola Lidbetter (4175434)
Rebecca Pedley (3926201)
Jo Molle (4175428)
Emily Peckham (2552590)
Jasmin Knopp-Hoffer (4175422)
Owen Price (451770)
Janice Connell (3807247)
Margaret Heslin (3583244)
Christopher Foley (3120528)
Faye Plummer (4175425)
Christopher Roberts (2161816)

June 2017

<p>Outcome measure summary statistics and intervention effects at 3, 6, and 12 months.</p

Sequence and duration of interventions and assessments periods during the entire experimental protocol.

François Trudeau (6619475)
Kim Gilbert (6619478)
Annie Tremblay (4267930)
Thomas A. Tompkins (2695411)
Roger Godbout (6619481)
Guy Rousseau (125035)

April 2019

Sequence and duration of interventions and assessments periods during the entire experimental protoc...

Patient scores on measures for treatment adherence and patient-related determinants of adherence taken at baseline and six months (N = 139).

Jennita G. Meinema (782715)
Nynke van Dijk (462651)
Erik J. A. J. Beune (467309)
Debbie A. D. C. Jaarsma (782716)
Henk C. P. M. van Weert (231560)
Joke A. Haafkens (530877)

August 2015

<p>SD = Standard deviation</p><p>Patient scores on measures for treatment adherence and patient-rela...

Prescribed amount and number of years of prescription of fall-risk-increasing drugs during the study period (2006–2012).

Anna Axmon (3478604)
Magnus Sandberg (3541586)
Gerd Ahlström (3541583)
Patrik Midlöv (3549812)

June 2018

<p>Prescribed amount and number of years of prescription of fall-risk-increasing drugs during the st...

Anti-diabetic and anti-hypertensive treatment in intervention group and in control group at baseline and at 12-month follow-up (FU).

Xavier Debussche (4785873)
Stéphane Besançon (628922)
Maryvette Balcou-Debussche (4785876)
Cyril Ferdynus (3220950)
Hélène Delisle (671273)
Laetitia Huiart (498956)
Assa T. Sidibe (4785879)

January 2018

<p>Anti-diabetic and anti-hypertensive treatment in intervention group and in control group at basel...

Adherence rate of confirmed cases undergoing treatment by stakeholder referring.

Paschal Kum Awah (43531)
Alphonse Um Boock (267187)
Ferdinand Mou (421869)
Joseph Tohnain Koin (5018447)
Evaristus Mbah Anye (5018450)
Djeunga Noumen (421870)
Mark Nichter (727792)

March 2018

<p>Adherence rate of confirmed cases undergoing treatment by stakeholder referring.</p

Observed average monthly HTS and VMMC rates by study condition, over entire study period and within the first six months of intervention implementation.

Stephen M. Weiss (6804122)
Kasonde Bowa (2813896)
Robert Zulu (16813963)
Violeta J. Rodriguez (3174705)
Ryan R. Cook (8812859)
Deborah L. Jones (3174693)

January 2024

Observed average monthly HTS and VMMC rates by study condition, over entire study period and within ...

Drug resistance and treatment efficacy in the group infected with subtype D.

Miłosz Parczewski (332730)
Magdalena Leszczyszyn-Pynka (332731)
Dorota Bander (332732)
Anna Urbanska (332734)
Anna Boroń-Kaczmarska (332736)

February 2013

<p>*Percentage expressed adherence based on the number of months of medications dispensed by the num...

For all study patients, patient median Hb, median TSAT, mean IV iron and mean EPO administered in the protocol period 12 months before study start and the 18-month CQI period.

Jonathan A. Lorch (566667)
Victor E. Pollak (566668)

May 2014

<p>For all study patients, patient median Hb, median TSAT, mean IV iron and mean EPO administered in...

Outcomes at 12 months follow-up compared between the intervention and the control groups.

Anna Barker (3448526)
Peter Cameron (848182)
Leon Flicker (95283)
Glenn Arendts (84730)
Caroline Brand (3448523)
Christopher Etherton-Beer (398694)
Andrew Forbes (454446)
Terry Haines (3631453)
Anne-Marie Hill (415096)
Peter Hunter (222839)
Judy Lowthian (3566432)
Samuel R. Nyman (6733592)
Julie Redfern (3221304)
De Villiers Smit (6733595)
Nicholas Waldron (3500894)
Eileen Boyle (6733598)
Ellen MacDonald (6733601)
Darshini Ayton (4065070)
Renata Morello (3448529)
Keith Hill (4065067)

May 2019

Outcomes at 12 months follow-up compared between the intervention and the control groups.</p

Treatment parameters of the two study groups at the baseline and during follow-up period.

Luciano A. Pedrini (6392159)
Adam M. Zawada (847589)
Anke C. Winter (6392162)
Jenny Pham (6392165)
Gudrun Klein (6392168)
Melanie Wolf (3103785)
Astrid Feuersenger (6392171)
Pio Ruggiero (6392174)
Annalisa Feliciani (6392177)
Carlo Barbieri (848258)
Adelheid Gauly (355519)
Bernard Canaud (177330)
Stefano Stuard (2552848)

February 2019

Treatment parameters of the two study groups at the baseline and during follow-up period.</p

Adherence to clinical preventive recommendations among diabetes patients according to study variables.

Isabel Jimenez-Trujillo (509331)
Rodrigo Jiménez-García (320379)
Jesus Esteban-Hernández (2209084)
Valentin Hernández-Barrera (2209078)
Pilar Carrasco Garrido (2209075)
Miguel A. Salinero-Fort (310193)
Juan Cardenas-Valladolid (2209081)
Ana López-de-Andrés (2190292)

June 2015

<p>Adherence to clinical preventive recommendations among diabetes patients according to study varia...

Cost-effectiveness acceptability curve: proportion adherent over the intervention period.

Catherine Henderson (811342)
Martin Knapp (146158)
Ksenija Yeeles (342120)
Stephen Bremner (119242)
Sandra Eldridge (80747)
Anthony S. David (720515)
Nicola O’Connell (645718)
Tom Burns (811343)
Stefan Priebe (117382)

October 2015

<p>Cost-effectiveness acceptability curve: proportion adherent over the intervention period.</p

Treatment efficacy during the 12-week observation period: Control vs. FMT groups (intention-to-treat [ITT] and per-protocol [PP] analysis).

Hongliang Tian (529301)
Xiaolong Ge (1758829)
Yongzhan Nie (124038)
Linfeng Yang (516708)
Chao Ding (1402099)
Lynne V. McFarland (3716476)
Xueying Zhang (460267)
Qiyi Chen (1663033)
Jianfeng Gong (177593)
Ning Li (45258)

February 2017

<p>Treatment efficacy during the 12-week observation period: Control vs. FMT groups (intention-to-tr...

Change in steps/day between baseline and 12-month follow-up after a behavioral physical activity intervention.

Maria Koreny (54716)
Heleen Demeyer (500670)
Ane Arbillaga-Etxarri (845881)
Elena Gimeno-Santos (845883)
Anael Barberan-Garcia (845884)
Marta Benet (188966)
Eva Balcells (582606)
Eulàlia Borrell (6714437)
Alicia Marin (1653766)
Diego A. Rodríguez Chiaradía (6714440)
Pere Vall-Casas (845887)
Jordi Vilaró (845886)
Robert Rodríguez-Roisin (6714443)
Judith Garcia-Aymerich (582609)

May 2019

Change in steps/day between baseline and 12-month follow-up after a behavioral physical activity int...

Outcome measure summary statistics and intervention effects at 3, 6, and 12 months.

Karina Lovell (52502)
Peter Bower (52501)
Judith Gellatly (4175419)
Sarah Byford (405086)
Penny Bee (456567)
Dean McMillan (628092)
Catherine Arundel (3558773)
Simon Gilbody (52503)
Lina Gega (4175413)
Gillian Hardy (3807229)
Shirley Reynolds (4175416)
Michael Barkham (615633)
Patricia Mottram (4175431)
Nicola Lidbetter (4175434)
Rebecca Pedley (3926201)
Jo Molle (4175428)
Emily Peckham (2552590)
Jasmin Knopp-Hoffer (4175422)
Owen Price (451770)
Janice Connell (3807247)
Margaret Heslin (3583244)
Christopher Foley (3120528)
Faye Plummer (4175425)
Christopher Roberts (2161816)

June 2017

<p>Outcome measure summary statistics and intervention effects at 3, 6, and 12 months.</p

Sequence and duration of interventions and assessments periods during the entire experimental protocol.

François Trudeau (6619475)
Kim Gilbert (6619478)
Annie Tremblay (4267930)
Thomas A. Tompkins (2695411)
Roger Godbout (6619481)
Guy Rousseau (125035)

April 2019

Sequence and duration of interventions and assessments periods during the entire experimental protoc...

Patient scores on measures for treatment adherence and patient-related determinants of adherence taken at baseline and six months (N = 139).

Jennita G. Meinema (782715)
Nynke van Dijk (462651)
Erik J. A. J. Beune (467309)
Debbie A. D. C. Jaarsma (782716)
Henk C. P. M. van Weert (231560)
Joke A. Haafkens (530877)

August 2015

<p>SD = Standard deviation</p><p>Patient scores on measures for treatment adherence and patient-rela...

Prescribed amount and number of years of prescription of fall-risk-increasing drugs during the study period (2006–2012).

Anna Axmon (3478604)
Magnus Sandberg (3541586)
Gerd Ahlström (3541583)
Patrik Midlöv (3549812)

June 2018

<p>Prescribed amount and number of years of prescription of fall-risk-increasing drugs during the st...

Anti-diabetic and anti-hypertensive treatment in intervention group and in control group at baseline and at 12-month follow-up (FU).

Xavier Debussche (4785873)
Stéphane Besançon (628922)
Maryvette Balcou-Debussche (4785876)
Cyril Ferdynus (3220950)
Hélène Delisle (671273)
Laetitia Huiart (498956)
Assa T. Sidibe (4785879)

January 2018

<p>Anti-diabetic and anti-hypertensive treatment in intervention group and in control group at basel...

Adherence rate of confirmed cases undergoing treatment by stakeholder referring.

Paschal Kum Awah (43531)
Alphonse Um Boock (267187)
Ferdinand Mou (421869)
Joseph Tohnain Koin (5018447)
Evaristus Mbah Anye (5018450)
Djeunga Noumen (421870)
Mark Nichter (727792)

March 2018

<p>Adherence rate of confirmed cases undergoing treatment by stakeholder referring.</p

Observed average monthly HTS and VMMC rates by study condition, over entire study period and within the first six months of intervention implementation.

Stephen M. Weiss (6804122)
Kasonde Bowa (2813896)
Robert Zulu (16813963)
Violeta J. Rodriguez (3174705)
Ryan R. Cook (8812859)
Deborah L. Jones (3174693)

January 2024

Observed average monthly HTS and VMMC rates by study condition, over entire study period and within ...

Drug resistance and treatment efficacy in the group infected with subtype D.

Miłosz Parczewski (332730)
Magdalena Leszczyszyn-Pynka (332731)
Dorota Bander (332732)
Anna Urbanska (332734)
Anna Boroń-Kaczmarska (332736)

February 2013

<p>*Percentage expressed adherence based on the number of months of medications dispensed by the num...

For all study patients, patient median Hb, median TSAT, mean IV iron and mean EPO administered in the protocol period 12 months before study start and the 18-month CQI period.

Jonathan A. Lorch (566667)
Victor E. Pollak (566668)

May 2014

<p>For all study patients, patient median Hb, median TSAT, mean IV iron and mean EPO administered in...